Phospho-PTEN (Ser380) (NA9) rabbit mAb
Catalog #: 2236
20 μL is enough antibody for at least 20 Western blots.
Customers Also Viewed
PTEN has been identified as a tumor suppressor gene and has been found to be mutated in a significant number of human cancers, including prostate, brain, and breast cancer. PTEN shares sequence homology with the protein-tyrosine phosphatase (PTPase) family of proteins and negatively regulates the PI3K/Akt pathway. PTEN de-phosphorylates target proteins, and recombinant PTEN has been shown to have phosphoinositide 3-phosphhatase and inositol phosphate 3-phosphatase activity. Studies of primary tumor cells show a loss of PTEN expression after metastasis to the brain, via astrocyte-derived microRNAs. A cluster of phosphorylation sites (S380, T382, T383, and S385) in the C-terminal tail of PTEN drive a conformational change that reduces PTEN activity by inhibiting membrane interactions.
|Validated Reactivity||Human, Mouse|
|Cross Reactivity||Predicted to work with mouse, rat, and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Ser380 of human phospho PTEN|
|Formulation||1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA|
|Recommended Usage||1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|Pseudonyms||Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase, Mutated in multiple advanced cancers 1, MMAC1, Phosphatase and tensin homolog, TEP1|
|References||Li J, Yen C, Liaw D, et al. (1997) Science. 275:1943-1947.
Maehama T, and Dixon JE. (1998) Journal of Biological Chemistry. 273:13375-13378.
Zhang L, Zhang S, You J, et al. (2015) Nature. 527:100-104.
Chen Z, Dempsey DR, Thomas SN, Hayward D, Bolduc DM, and Cole PA. (2016) Journal of Biological Chemistry. 291:14160-14169.
Flow cytometric analysis of A431 cells, untreated and unstained as negative control (blue) or untreated and stained (green) or treated with lambda phosphatase and stained (red) using Phospho-PTEN (S380) antibody, PTENS380-NA9 at 0.1 ug/mL, Cat. #2236.
Peptide blocking flow cytometric analysis of A431 cells secondary antibody only negative control (light blue) or untreated (red) or treated with EGF (green) or untreated and blocked with phospho-peptide (black) or EGF and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or EGF and blocked with non-phospho peptide (purple) using Phospho-PTEN (S380) antibody PTENS380-NA9 0.05 µg/mL. Cat. #2236.
PTENS380-NA9 recognizes basal phosphorylation levels in mouse cells. Flow cytometric analysis of L929 cells secondary antibody only (blue) or 0.1 µg/mL of isotype control Cat. #2141 (orange) or of Phospho-PTEN (S380) antibody PTENS380-NA9 (green) Cat. #2236.
Phospho-PTEN (Ser380/Thr382/383) (E4) rabbit mAbCatalog #: 2131
Phospho-PTEN (Ser380/Thr382/383) (E4) rabbit mAb PE conjugateCatalog #: 2132
Phospho-PTEN (Ser380) (NA9) rabbit mAb FITC conjugateCatalog #: 2238
Phospho-PTEN (Ser380) (NA9) rabbit mAb APC conjugateCatalog #: 2239